IFNB1 Antikörper (AA 101-184)

Produktnummer ABIN728113

Produktdetails anti-IFNB1 Antikörper

Target: IFNB1 (Interferon, beta 1, Fibroblast (IFNB1))

Bindungsspezifität: AA 101-184

Reaktivität: Human, Maus

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser IFNB1 Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), ELISA, Immunofluorescence (Cultured Cells) (IF (cc)), Immunofluorescence (Paraffin-embedded Sections) (IF (p)), Immunohistochemistry (Frozen Sections) (IHC (fro))

Kreuzreaktivität: Human, Maus

Homologie: Rat

Aufreinigung: Purified by Protein A.

Immunogen: KLH conjugated synthetic peptide derived from mouse IFNB1

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: WB 1:300-5000
ELISA 1:500-1000
IHC-F 1:100-500
IF(IHC-P) 1:50-200
IF(IHC-F) 1:50-200
IF(ICC) 1:50-200

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: 1 μg/μL

Buffer: 0.01M TBS( pH 7.4) with 1 % BSA, 0.02 % Proclin300 and 50 % Glycerol.

Konservierungsmittel: ProClin

Vorsichtsmaßnahmen: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.

Lagerung: 4 °C,-20 °C

Informationen zur Lagerung: Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.

Haltbarkeit: 12 months

Details zu IFNB1

Target: IFNB1 (Interferon, beta 1, Fibroblast (IFNB1))

Andere Bezeichnung: IFN-beta (IFNB1 Produkte)

Synonyme: IFB antikoerper, IFF antikoerper, IFNB antikoerper, IFN-beta antikoerper, Ifb antikoerper, Ifnb antikoerper, IFNb antikoerper, interferon beta 1 antikoerper, interferon beta 1, fibroblast antikoerper, interferon, beta 1, fibroblast antikoerper, IFNB1 antikoerper, Ifnb1 antikoerper

Hintergrund:

Synonyms: Fibroblast interferon, N-Beta, N _, _-N, B, _ N, _N, F, N beta, NB 1, NB , NB1, Interferon beta 1 fibroblast , Beta-N, Beta N, Interferon beta precursor, MGC96956_ Interferon beta_ Interferon-beta.

Background: The mammalian type I Inteferons (IFN1) are produced in response to viral infection and other inducers. They are divided into alpha and beta subtypes leukocytes and fibroblasts reactivity. The human IFN alphas are encoded by a family of at least 15 different genes, while IFN beta is the unique member of its subtype. There is approximately 50 % amino acid homology between the alpha and beta subtypes. Both IFN subtypes are pleiotropic cytokines and have a similar range of biological activities. Differences between alpha subtypes, and between IFN alpha and betas, are in potency and cell type specific activities. In particular, IFN beta elicits a markedly higher antiproliferation response in some cell types such as, embryonal carcinoma, melanoma and melanocytes than do IFN alphas. Higher potency of IFN beta in treatment of multiple sclerosis and certain cancers has been observed. Type I IFNs signal through binding to a common cell surface receptor. Two chains of the receptor, IFNAR1 and IFNAR2, have been identified. Both chains are necessary for function and in the absence of either there is neither high affinity binding nor biological activity. The intracellular portions of the receptor subunits are bound by tyrosine kinases, Jak1 and Tyk2, members of the Janus kinase family. Upon ligand binding these kinases are activated and phosphorylate members of the STAT family of transcription factors, as well as IFNAR1 and 2.

Gen-ID: 24481

UniProt: P01575

Pathways: JAK-STAT Signalweg, T-Zell Rezeptor Signalweg, TLR Signalweg, Regulation of Leukocyte Mediated Immunity, Production of Molecular Mediator of Immune Response, Positive Regulation of Endopeptidase Activity, Hepatitis C, Autophagie, Inflammasome